Form a 10 marls answer on alcoholic hepatitis

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive information to write a detailed 10-mark exam answer on alcoholic hepatitis. Here it is:

Alcoholic Hepatitis - 10 Mark Answer

Definition

Alcoholic hepatitis (AH) is an acute inflammatory syndrome of the liver occurring in the setting of prolonged and heavy alcohol consumption. It represents one stage of a disease spectrum that ranges from steatosis (fatty liver) to steatohepatitis, fibrosis, and ultimately cirrhosis and hepatocellular carcinoma (HCC). - Rosen's Emergency Medicine, p. 2479; Goldman-Cecil Medicine, p. 3416

Epidemiology and Risk Factors

Nearly 90% of individuals who consume >6 drinks/day (>60 g/day) develop alcoholic fatty liver; however, only 15-30% of patients with alcohol-associated liver disease (ALD) develop alcoholic hepatitis. - Symptom to Diagnosis, p. 461; Goldman-Cecil, p. 3418
Female sex carries higher risk - cirrhosis can develop at >20 g/day in women vs. >60-80 g/day in men, with peak incidence a decade earlier in women. - Goldman-Cecil, p. 3432
Other risk factors: African-American and Hispanic ethnicity, obesity, drinking outside meal times, binge drinking, and concomitant hepatitis C infection. - Symptom to Diagnosis, p. 461
Nearly 50% of patients with alcoholic hepatitis have pre-existing cirrhosis. - Goldman-Cecil, p. 3418

Pathogenesis

Liver injury occurs through two broad mechanisms:

Hepatocyte-direct effects: Altered redox state from alcohol/aldehyde dehydrogenase reactions; oxidative stress via CYP2E1 induction and mitochondrial dysfunction; lipid peroxidation; protein adduct formation; altered methionine/folate metabolism causing ER stress.
Kupffer cell-mediated effects: Chronic alcohol increases gut permeability, leading to portal endotoxemia which activates Kupffer cells. These release proinflammatory mediators - TNF-alpha (causes hepatocyte apoptosis), TGF-beta1 and PDGF (activate stellate cells, promote fibrosis), and interleukins 1, 6, 8, and 10. - Goldman-Cecil, p. 3430

Clinical Features

Symptoms mimic viral hepatitis and include:

Fever, right upper quadrant pain, nausea, vomiting, anorexia, weight loss, and jaundice
Hepatomegaly (70% of patients)
In severe cases: ascites, encephalopathy, and transient portal hypertension
Malnutrition is present in up to 90% of patients
Hypoglycemia is common, secondary to caloric insufficiency, depleted glycogen stores, and suppressed gluconeogenesis. - Rosen's Emergency Medicine, p. 2485; Washington Manual, p. 5358-5362

Diagnosis

Alcoholic hepatitis is primarily a clinical diagnosis. Key diagnostic criteria (as used in clinical trials):

History of excessive alcohol consumption
Serum bilirubin > 4.5 mg/dL
AST < 500 units/L, ALT < 300 units/L
Exclusion of acute viral, autoimmune, obstructive, or malignant liver disease. - Symptom to Diagnosis, p. 461

Laboratory findings:

AST:ALT ratio > 2:1 (seen in 70-80% of patients; ratios >3 are more specific) - the hallmark lab finding distinguishing it from viral hepatitis
Elevated GGT; GGT:ALP ratio often > 2.5
Hyperbilirubinemia (conjugated), elevated PT/INR
Poor prognostic labs: renal failure, leukocytosis, markedly elevated bilirubin, PT/INR not normalizing with vitamin K. - Washington Manual, p. 5375-5379; Swanson's Family Medicine, p. 3220

Imaging: Ultrasound or CT helps rule out other diagnoses; may show fatty infiltration, hepatomegaly, ascites, or cirrhosis.

Liver biopsy (gold standard but not always required) shows:

Hepatocyte ballooning
Mallory-Denk bodies (Mallory bodies) - eosinophilic intracytoplasmic inclusions
Lobular inflammation with neutrophilic infiltrates
Hepatocyte necrosis
Perivenular and pericellular fibrosis, ductal proliferation, fatty changes. - Washington Manual, p. 5397; Schwartz's Principles of Surgery, p. 1242

Severity Scoring

Several validated scoring systems exist to risk-stratify patients:

Score	Formula	Threshold	Significance
Maddrey's Discriminant Function (mDF)	4.6 × (patient PT - control PT) + serum bilirubin	≥ 32 = severe	93% 1-month survival if <32; 68% if ≥32
MELD Score	Incorporates bilirubin, INR, creatinine	> 11 comparable to mDF ≥ 32; > 20 at 1 week = 91% sensitivity for 30-day mortality
Glasgow Alcoholic Hepatitis Score (GAHS)	Age, WBC, BUN, PT/INR, bilirubin	≥ 9 = severe	81% accuracy predicting 28-day mortality
Lille Model	Age, renal insufficiency, albumin, PT, bilirubin (day 0 vs. day 7 on steroids)	≥ 0.45 = poor response to steroids	Score ≥0.45: 25% 6-month survival vs. 85% if <0.45

Symptom to Diagnosis, p. 461; Washington Manual, p. 5383-5391

Treatment

1. Abstinence

The cornerstone of therapy for all forms of ALD. With cessation, steatosis may reverse within 2-4 weeks. - Harrison's Principles of Internal Medicine 22E, p. 2753

2. Nutritional Support

Malnutrition is nearly universal. Achieving > 21.5 kcal/kg body weight/day is associated with better survival. Enteral feeding (oral or small-bore feeding tube) is preferred; TPN is used if needed. Folate, thiamine, and vitamin K supplementation are required. - Harrison's, p. 2753; Swanson's, p. 3224

3. Corticosteroids (for severe disease, mDF ≥ 32)

Prednisolone 40 mg/day PO for 28 days (preferred over prednisone, which requires hepatic conversion to active form), followed by a taper over 2-4 weeks
Improves short-term (28-day) mortality but not medium/long-term (90-day, 1-year) mortality
Contraindicated in active infection, GI bleeding, renal failure
Lille score at day 7: if bilirubin does not decrease (Lille score ≥ 0.45), steroids should be stopped - indicates non-response. - Washington Manual, p. 5416; Harrison's, p. 2753

4. N-Acetylcysteine (NAC)

Modest evidence that IV NAC plus glucocorticoids may improve short-term survival in AH with mDF > 32. - Harrison's, p. 2753

5. Pentoxifylline

A non-selective phosphodiesterase inhibitor; 400 mg PO three times daily for 4 weeks
Previously used as an alternative to steroids (especially in the presence of infection)
Recent evidence (STOPAH trial) showed it did not improve survival; considered in patients intolerant of corticosteroids. - Washington Manual, p. 5418; Symptom to Diagnosis, p. 461

6. Alcohol Use Disorder Treatment

Naltrexone - most strongly supported by placebo-controlled trials for alcohol use disorder
Acamprosate calcium and baclofen may help reduce craving in patients with cirrhosis. - Washington Manual, p. 5406; Harrison's, p. 2753

7. Liver Transplantation

Historically requires 6 months of documented sobriety prior to evaluation
For highly selected patients with severe AH who fail medical therapy, early liver transplantation (without 6 months of sobriety) is an emerging, evidence-supported option in patients with excellent social support who have not had a prior liver transplant. - Washington Manual, p. 5423

Prognosis

3-month mortality: 15% (mild AH) to 55% (severe AH) - Symptom to Diagnosis, p. 461
Alcoholic cirrhosis prognosis:
- 5-year survival 75% with abstinence
- 5-year survival 50% if drinking continues
- 5-year survival 35% once cirrhosis complications appear - Symptom to Diagnosis, p. 461
Risk of HCC in decompensated alcohol-associated cirrhosis: ~1% per year - Rosen's, p. 2479
Despite abstinence, cirrhosis will develop in 5-15% of patients with steatosis; 30% if drinking continues. - Symptom to Diagnosis, p. 461

Summary Table: Alcoholic Hepatitis at a Glance

Feature	Key Point
Classic lab finding	AST:ALT > 2:1
Histology hallmark	Mallory-Denk bodies + neutrophilic infiltration
Severity cutoff	mDF ≥ 32 = severe disease
First-line treatment	Prednisolone 40 mg/day x 28 days
Response assessment	Lille score at day 7
Cornerstone of all stages	Alcohol abstinence

Sources: Rosen's Emergency Medicine | Harrison's Principles of Internal Medicine 22E | The Washington Manual of Medical Therapeutics | Goldman-Cecil Medicine | Symptom to Diagnosis: An Evidence-Based Guide, 4th Ed | Swanson's Family Medicine Review

This is a shared conversation. Sign in to Orris to start your own chat.